Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Zimmer Biomet stock upgraded to buy by Argus

EditorAhmed Abdulazez Abdulkadir
Published 21/05/2024, 09:42 pm
ZBH
-

On Tuesday, Zimmer Biomet Holdings Inc. (NYSE:ZBH) received an upgrade from a Hold to a Buy rating by a research firm. The firm set a new price target for the medical device company at $150.00. The upgrade is a result of Zimmer Biomet's strategic focus on launching new products and engaging in mergers and acquisitions to stimulate future growth.

The company's recent initiatives include the ROSA system, which is designed to assist in robotic surgeries for the implantation of replacement knee, hip, and shoulder joints, as well as its application in neurosurgery. Zimmer Biomet is also introducing a cementless knee implant that promises to reduce procedure times and improve staffing efficiency in hospitals.

These innovations are part of Zimmer Biomet's broader plan to launch over 40 new products in the next two to three years. This ambitious product rollout is expected to address the growing demand for medical procedures that enhance mobility and quality of life, particularly in aging populations across advanced economies in Asia, Europe, and North America.

InvestingPro Insights

Zimmer Biomet Holdings Inc. (NYSE:ZBH) is capturing the attention of investors and analysts alike with its strategic maneuvers in the medical device industry. According to recent data from InvestingPro, the company boasts a market capitalization of $24.49 billion and is trading at an adjusted P/E ratio of 20.41 for the last twelve months as of Q1 2024. This valuation comes in the wake of a 4.85% revenue growth during the same period, underscoring the company's progressive financial trajectory.

In line with the company's forward-thinking approach, the InvestingPro Tips highlight that management has been actively repurchasing shares, signaling confidence in the company's future performance. Moreover, Zimmer Biomet has consistently paid dividends for 13 consecutive years, with a modest dividend yield of 0.81% as of the latest data, and analysts project the company to remain profitable this year, reinforcing the company's financial stability.

For those looking to delve deeper into Zimmer Biomet's potential, there are additional InvestingPro Tips available that provide a more nuanced understanding of the company's prospects. With a coupon code PRONEWS24, interested readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these insights. There are 6 more tips available on InvestingPro that can help investors make informed decisions about Zimmer Biomet.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.